Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nexgel Inc (NXGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NXGL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -35.78% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.24M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 58659 | Beta 0.62 | 52 Weeks Range 1.84 - 5.10 | Updated Date 04/1/2025 |
52 Weeks Range 1.84 - 5.10 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.77% | Operating Margin (TTM) -27.66% |
Management Effectiveness
Return on Assets (TTM) -21.22% | Return on Equity (TTM) -61.59% |
Valuation
Trailing PE - | Forward PE 49.75 | Enterprise Value 21261999 | Price to Sales(TTM) 2.33 |
Enterprise Value 21261999 | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 2.45 | Enterprise Value to EBITDA -0.85 | Shares Outstanding 6792950 | Shares Floating 6322465 |
Shares Outstanding 6792950 | Shares Floating 6322465 | ||
Percent Insiders 20.2 | Percent Institutions 6.08 |
Analyst Ratings
Rating 4 | Target Price 6 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nexgel Inc
Company Overview
History and Background
Nexgel, Inc. (NXGL) is a technology company focused on developing and commercializing advanced hydrogels. Founded in 2015, Nexgel aims to disrupt traditional medical adhesives and wound care markets with its innovative gel formulations.
Core Business Areas
- Advanced Hydrogels: Develops and manufactures high-water content hydrogels for medical and cosmetic applications.
- Medical Adhesives: Creates strong, biocompatible adhesives for wound closure and surgical procedures.
- Wound Care: Offers advanced wound dressings that promote healing and reduce scarring.
Leadership and Structure
Adam R.Carey is the CEO. The company operates with a team focused on research and development, manufacturing, and sales/marketing.
Top Products and Market Share
Key Offerings
- Nexgel Adhesives: A line of biocompatible adhesives designed for wound closure and surgical applications. Market share data is not publicly available. Competitors include 3M (MMM), Johnson & Johnson (JNJ), and Medtronic (MDT).
- Nexgel Wound Dressings: Advanced wound dressings that promote faster healing and minimize scarring. Market share data is not publicly available. Competitors include Smith & Nephew (SNN), Convatec (CTEC), and Mu00f6lnlycke Health Care.
Market Dynamics
Industry Overview
The medical adhesives and wound care markets are large and growing, driven by an aging population, increasing rates of chronic diseases, and advancements in medical technology.
Positioning
Nexgel positions itself as an innovator in hydrogel technology, offering superior performance and biocompatibility compared to traditional products. Their competitive advantage lies in proprietary hydrogel formulations.
Total Addressable Market (TAM)
The TAM for advanced wound care and medical adhesives is estimated to be billions of dollars globally. Nexgel is positioned to capture a portion of this market with its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative hydrogel technology
- Strong R&D capabilities
- Proprietary formulations
- Potential for disruptive market entry
Weaknesses
- Limited market presence
- Dependence on strategic partnerships
- Limited financial resources
- Lack of brand recognition
Opportunities
- Expanding into new medical applications
- Strategic partnerships with established medical device companies
- Increasing adoption of advanced wound care products
- Growing demand for biocompatible adhesives
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
- Pricing pressure
Competitors and Market Share
Key Competitors
- MMM
- JNJ
- MDT
- SNN
- CTEC
Competitive Landscape
Nexgel faces intense competition from established players with greater resources and market presence. Nexgelu2019s competitive advantage lies in its superior hydrogel technology, but the company needs to scale up manufacturing and sales to effectively compete.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal, with revenues still in early stages.
Future Projections: Future growth projections depend on successful commercialization of products and securing partnerships. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include expanding product portfolio and securing partnerships with healthcare providers.
Summary
Nexgel Inc. is a high-risk, high-reward company with innovative hydrogel technology but limited market presence. The company needs to secure strategic partnerships and scale up production to effectively compete with established players. Successful commercialization of its products is crucial for future growth. Investors should be aware of the high risks associated with investing in this emerging growth company.
Similar Companies
CTEC
Global X CleanTech ETF
CTEC
Global X CleanTech ETF
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
MMM
3M Company
MMM
3M Company
SNN
Smith & Nephew SNATS Inc
SNN
Smith & Nephew SNATS Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market research
- SEC.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexgel Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2021-12-22 | CEO, President & Director Mr. Adam R. Levy | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://nexgel.com |
Full time employees - | Website https://nexgel.com | ||
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name. It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.